-
The Auvi-Q epinephrine injector was pulled from the market in 2015 because of quality concerns. Now, the drug's maker says the problems have been solved and Auvi-Q will be available again in 2017.
-
Three former leaders of an influential task force that issues guidelines for preventive care says insurance coverage for highly rated tests and services shouldn't be mandatory.
-
The company's lobbying of state legislatures is just one factor in EpiPen's dominance of the market. Manufacturers of competing devices have struggled to gain a foothold.